Medtronic's Heart Devices Outpace Med-Tech Growth
Medtronic (NYSE:MDT) reported strong fiscal Q1 results for 2027 with $9.8 billion in revenue and organic growth of 13.7%, driven largely by its cardiovascular business, which saw an 18.9% increase to $3.9 billion. The standout was Cardiac Ablation Solutions, growing at a remarkable 88% globally and surpassing the $2 billion trailing twelve-month revenue milestone ahead of schedule. Other high-performing segments included Diabetes (up 14.9%), Pelvic Health (15% growth), Robotics, and Cranial & Spinal Technologies (13%). Medtronic raised its full-year guidance for organic revenue to between 7.25% and 7.75%, with adjusted EPS expected in the range of $5.94–$6.00. However, not all segments performed equally well—Neuromodulation grew only 3%, Structural Heart saw low single-digit growth, and Medtronic faces a potential foreign exchange headwind between $50 million to $150 million for the year.
Tickers: $MDT
Topics: Cardiovascular Devices Market Share Expansion Medical Technology Revenue Growth